Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Tagworks Pharmaceuticals/

Library

Tagworks Pharmaceuticals

Tagworks Pharmaceuticals Website, Blog & Press Pages - aVenture Research

Library

tagworkspharma.comCrawled Nov 1, 2026

Topics

Publication type

Search the library

Content origin

Row density

Product

2 pages

Our Pipeline/pipeline
Tagworks’ lead program, TGW101, targets TAG72, a non-internalizing clinically validated pan-carcinoma target, present in several solid tumors, which cannot be effectively addressed with current ADC technologies.
Our Technology/our-technology
Enabling the selective on-target release and activation of a wide range of therapeutics, including small molecule prodrugs, antibody-drug conjugates, and caged proteins.

Blog

6 pages

Click chemistry targets antibody-drug conjugates for the clinic/click-chemistry-targets-antibody-drug-conjugates-for-the-clinic
Memorial Sloan Kettering Cancer Center researchers are testing a diagnostic that uses bioorthogonal ‘click’ chemistry to combine a radioisotope and antibody in humans.
Current Opinion in Chemical Biology features Tagworks review/current-opinion-in-chemical-biology-features-tagworks-review
Tagworks discusses extending pretargeted radioimmuno-imaging and -therapy, initially tested in mice, toward human applications.
Paper on improved antibody tag in Molecular Pharmaceutics/paper-on-improved-antibody-tag-in-molecular-pharmaceutics
Tagworks developed an antibody tag with improved pharmacokinetics and stability, increasing tumor uptake of a radiolabeled pretargeting probe in tests.
Tagworks paper in Bioconjugate Chemistry/tagworks-paper-in-bioconjugate-chemistry
Antibody tags with 10-fold increased reactivity and enhanced in vivo stability - Check the paper on 'Highly reactive trans-cyclooctene tags with improved stability for Diels-Alder chemistry in living systems' published in Bioconjugate Chemistry 2013, 24 ,7, 1210-1217 doi:10.1021/bc400153y

Press

6 pages

Click to release - Tagworks publishes new approach to selective bioorthogonal release/click-to-release-tagworks-publishes-new-approach-to-selective-bioorthogonal-release
Tagworks modified the inverse-electron-demand-Diels-Alder reaction to achieve selective bioorthogonal release, enabling chemically triggered activation of tumor-bound ADCs.
New collaboration/new-collaboration
Top-5 pharma company and Tagworks start collaboration on companion diagnostics.
Tagworks and the University of Missouri-Columbia receive $ 585k NIH grant/tagworks-and-the-university-of-missouri-columbia-receive-585k-nih-grant
Tagworks and the University of Missouri-Columbia secured an NIH IMAT grant for a project on in vivo metal-free cycloaddition chemistry for pretargeted cancer radiotherapy.
Tagworks features in Medicines/tagworks-features-in-medicines
The latest edition of Medicines, a Dutch journal on drug development, features Tagworks Pharmaceuticals in the start-up sections. The article by Rik Nijland appeared in Medicines 1, February 2015 (in Dutch) 24_25_med1_startup

Careers & Hiring

1 page

Join us in our mission/careers

Team

6 pages

Bianca Matthee, MSc., PharmD./team/bianca-matthee-msc-pharmd
Chris Martin, DPhil/team/chris-martin
Krisztina Nemenyi, MSc/team/krisztina-nemenyi-msc
Tagworks presents at Gordon Research Conference/marc-gordon-2014
Marc Robillard, CEO of Tagworks Pharmaceuticals, presented the company’s R&D progress at the Gordon Research Conference on Organic Reactions and Processes in 2014.

About

1 page

About/about

Contact

1 page

Contact/contact

Homepage

1 page

Homepage/
Tagworks pioneers Click-to-Release technology, using in vivo click chemistry to expand the therapeutic window of cancer treatments.

Privacy

1 page

Privacy Statement/privacy-statement
Tagworks Pharmaceuticals BV follows a GDPR-compliant privacy policy with no third-party cookies or data sales.

Terms & Conditions

1 page

Terms of Use/terms-of-use